

Expression of FGFR1, a novel fibroblast growth factor receptor, during embryonic development

BEAT TRUEB and SARA TAESCHLER

ITI Research Institute, University of Bern, Murtenstrasse 35, CH-3010 Bern, Switzerland

Received October 7, 2005; Accepted December 12, 2005

Abstract. FGFR1 is a novel member of the fibroblast growth factor receptor (FGFR) family. To investigate its expression during mammalian embryonic development, we have used the mouse system. Expression of *Fgfr1* is very low in mouse embryos of day 6 but steadily increases until birth. As demonstrated by *in situ* hybridization of 16-day-old embryos, the *Fgfr1* mRNA occurs in cartilaginous structures such as the primordia of bones and the permanent cartilage of the trachea, the ribs and the nose. In addition, some muscle types, including the muscles of the tongue and the diaphragm, express *Fgfr1* at relatively high level. In contrast, the heart and the skeletal muscles of the limbs, as well as many other organs (brain, lung, liver, kidney, gut) express *Fgfr1* only at basal level. It is conceivable that *Fgfr1* interacts with other Fgfrs, which are expressed in cartilage and muscle, to modulate FGF signaling.

Introduction

FGFR1 is a recently discovered member of the fibroblast growth factor receptor (FGFR) family (1). This family of transmembrane receptors is known to control the proliferation, differentiation and migration of cells in various tissues including bone, cartilage and muscle. The gene for FGFR1 is found in all vertebrates from fish to man, but it appears to be missing in invertebrates (2).

Originally, we isolated cDNA clones for FGFR1 from a subtracted cDNA library that had been prepared with the aim to identify novel cartilage-specific genes (1). Independently, two other research groups identified clones for the same receptor in cDNA libraries prepared from human embryos (3) and murine lymph node cells (4) and termed the novel protein FGFR5. The structure of FGFR1/FGFR5 is highly related to that of the other four FGFRs (5,6). It contains a signal peptide, three extracellular Ig-like domains and a single transmembrane domain. In contrast to the FGFRs, however,

the novel receptor is missing the intracellular tyrosine kinase domain, which would be required for signal transduction by transphosphorylation (5-8). Instead it contains a short, histidine-rich domain at its C-terminus that is not related to any other protein. Owing to the structural relationship of the extracellular domain and to the lack of the kinase domain, we have speculated that FGFR1 might function as a decoy receptor and modulate FGF signaling. Recombinant FGFR1 is able to interact with FGF2 (3,7), an observation that is in line with our assumption. Moreover, FGFR1 has a negative effect on cell proliferation when overexpressed in MG63 osteosarcoma cells, lending further support to the idea of a decoy receptor. On the other hand, the affinity of FGF2 for the novel receptor is relatively weak (K_d 10^{-8}), provoking questions about the nature of the authentic ligand under physiological conditions (7).

To learn more about the putative function of FGFR1, we set out to investigate its expression during development. Since potent antibodies against the FGFR1 protein are not yet available, we employed our cDNA clones for Northern blotting and *in situ* hybridization experiments to demonstrate the expression pattern of FGFR1 during mouse embryonic development.

Materials and methods

Northern blots. Total RNA was isolated from various mouse tissues with the aid of the RNeasy kit from Qiagen (Hilden, Germany). The tissues were homogenized in guanidinium isothiocyanate buffer, extracted with phenol/chloroform, followed by chloroform (9) and loaded onto the RNeasy columns. Purified RNA (10 μ g/lane) was separated on 1% agarose gels in the presence of formaldehyde and transferred to Nylon membranes by vacuum blotting. The membranes were hybridized at 42°C with the labeled cDNA probe in a buffer containing 50% formamide (10). After 24 h, the blots were washed and exposed to X-ray film or analyzed with a phosphorimager (Storm 840, Molecular Dynamics, Sunnyvale, CA). The probe corresponded to an *Xba*I/*Bam*HI fragment of the mouse *Fgfr1* cDNA (position 661-1417) that had been labeled with [α - 32 P] by the random primed oligolabeling method (11).

In situ hybridization. *In situ* hybridization experiments were performed essentially as described by Wälchli *et al* (12) with labeled RNA probes. Samples from 15- to 17-day-old mouse embryos were embedded in paraffin and cut into serial sections.

Correspondence to: Dr Beat Trueb, ITI Research Institute, University of Bern, Murtenstrasse 35, P.O. Box 54, CH-3010 Bern, Switzerland
E-mail: beat.trueb@iti.unibe.ch

Key words: cartilage, FGF, FGFR, fibroblast growth factor receptor, *in situ* hybridization




Figure 1. Expression of *Fgfr1* during mouse embryonic development. Total RNA from mouse embryos of 9.5-18.5 days post coitum was resolved on an agarose gel and transferred to a Nylon membrane. The membrane was hybridized with a radioactively labeled cDNA probe for mouse *Fgfr1*. The panel at the bottom shows the 18S ribosomal RNA stained with ethidium bromide as a loading control.

The mouse *Fgfr1* cDNA sequence (see above) was placed into the pSK⁺ vector and riboprobes were transcribed by T7 (anti-sense) or T3 (sense) RNA polymerase in the presence of ³⁵S-uridine 5'-triphosphate. The tissue sections were digested with proteinase K and hybridized with the labeled probes at 60°C. After 18 h, the slides were treated with RNase A and washed with 0.1X standard saline citrate at 65°C. The slides were then coated with NTB-2 emulsion (Eastman Kodak, Rochester, NY) and exposed for 3 days at 4°C. After developing with D-19 developer, the sections were stained with hematoxylin and eosin. Finally, the slides were inspected under a Nikon Eclipse E1000 microscope equipped with dark field optics.

Results

Expression of *Fgfr1* during embryogenesis. To investigate the relative expression of *Fgfr1* during embryogenesis, a Northern blot containing total RNA from mouse embryos of days 9.5-18.5 was hybridized with a ³²P-labeled cDNA probe (Fig. 1). Very low expression of *Fgfr1* was observed at day 9.5 as indicated by the faint band migrating with a relative mobility of 2600 nucleotides. This signal steadily increased until day 18.5. Prominent expression of *Fgfr1* was observed between days 15.5 and 18.5.

Expression of *Fgfr1* in different tissues. Mouse embryos of different stages were cut into sagittal sections and hybridized with ³⁵S-labeled RNA probes for mouse *Fgfr1* (Fig. 2). Control sections treated with the sense probe were consistently found to be negative (Fig. 2D). Sections from a 12.5-day-old embryo treated with the anti-sense probe did not reveal any distinct signal stronger than background. Sections from a 15.5-day-old embryo yielded a weak signal, which required electronic enhancement for clear visualization. Sections from 16.5- and 17.5-day-old embryos exhibited a prominent signal that could readily be photographed (Fig. 2A-C). Nevertheless, the signal was considerably weaker than the signal obtained




Figure 2. Expression of *Fgfr1* in late mouse embryos. Whole body sections of mouse embryos prepared at 15.5 (A), 16.5 (B and D) and 17.5 (C) days post coitum (16) were hybridized with radioactively labeled anti-sense (A-C) or sense (D) cRNA probes for mouse *Fgfr1*. The hybridization signal was visualized under the microscope by dark field optics.

with a control probe for β -actin (data not shown). Hybridization with our *Fgfr1* probe was found to occur primarily in structures of bone and cartilage, including the primordia of the vertebral bodies, the primordia of the pelvic bone as well as the permanent cartilage of the nose, the ribs and the trachea. A distinct signal was also noted in some muscular structures, such as the muscles of the tongue and the diaphragm. In contrast, the brain, the spinal cord, the thymus, the lung, the heart, the liver and the gut showed only background signal (Fig. 2).

Selected structures were inspected at higher magnification (Fig. 3). In the paw of the hind limb (Fig. 3A and B), faint expression of *Fgfr1* was observed in the primordia of the metatarsal bones, while the skin, the tendons and the loose connective tissue in between were negative. In the trachea (Fig. 3C and D), all tracheal rings were positive. The silver grains appeared to be evenly distributed throughout the cricoid cartilage, whereas the perichondrium contained barely any signal. Likewise, the costal cartilage of the ribs had silver grains distributed over the entire area, whereas the perichondrium appeared to be negative (Fig. 3E and F). The muscles on top of the ribs (musculus pectoralis superficialis and musculus pectoralis profundus) as well as the intercostal muscles were also clearly positive. Furthermore, a faint signal was observed at the location of the pleura, but this signal is




Figure 3. Expression of *Fgfr11* in cartilaginous structures. Selected sections from 17.5-day-old (A-D) and 16.5-day-old mouse embryos (E and F) were hybridized with an anti-sense probe for *Fgfr11* and inspected under dark field (A, C and E) and bright field (B, D and F) optics. (A) and (B) show consecutive, transversal sections through the distal part of the paw from the hind leg, scale bar 200 μ m. (C) and (D) show a sagittal section through the chest depicting the tracheal rings (cricoid cartilage). Cranial is to the left, scale bar 100 μ m. (E) and (F) represent a sagittal section through the chest depicting the ribs with costal cartilages 3, 4 and 5 as well as intercostal muscles. Cranial is to the top, scale bar 200 μ m.

difficult to interpret since it was also detected in the control section (Fig. 2D), but not in the section prepared from an older embryo (Fig. 2C).

The heart with ventricle and atrium appeared to be negative, but the aorta located just beneath the tracheal rings was prominently stained (Fig. 2C). At higher magnification, the silver grains appeared to be distributed evenly throughout the aortic wall (Fig. 4A and B). Likewise, the diaphragm contained silver grains distributed over the entire thickness of the muscle and did not reveal any substructures (Fig. 4C and D). An interesting pattern was observed with the tongue (Fig. 4E and F). While the tunica mucosa was negative and formed a black belt around the tongue, the longitudinal muscle bundles beneath the mucous membrane as well as the vertical muscle bundles spanning the tongue (13) were strongly positive and yielded a striking, striped pattern.

Northern blots. The results obtained by *in situ* hybridization were verified by Northern blotting experiments utilizing a 32 P-labeled cDNA probe that corresponded to the probe used for *in situ* hybridization. Total RNA was extracted from various tissues of newborn mice (9-27 days) and resolved on two agarose gels. After blotting and hybridization, our probe was found to bind specifically to the 2600 nucleotide band as noted above (Fig. 5). A fairly strong signal was observed with RNA from the cartilaginous structures of the sternum and the




Figure 4. Expression of *Fgfr11* in muscular tissues. Selected sections from 17.5-day-old mouse embryos were hybridized with an anti-sense probe for *Fgfr11* and inspected under dark field (A, C and E) and bright field optics (B, D and F). (A) and (B) show a section through the aorta, scale bar 50 μ m. (C) and (D) show a section through the diaphragm, scale bar 50 μ m. (E) and (F) show a sagittal section through the tongue, scale bar 200 μ m.




Figure 5. Expression of *Fgfr11* in several mouse tissues. Total RNA was extracted from new-born mice, separated on two agarose gels and transferred to Nylon membranes. The blots were hybridized with a cDNA probe for mouse *Fgfr11*. Note that the blot on the right was exposed five times as long as the blot on the left to visualize faint expression. RNA from heart is shown on both blots and may serve as an internal reference. At the bottom, the 28S ribosomal RNA stained with ethidium bromide is included as a loading control.

vertebral bodies. A prominent signal was also obtained with RNA from the tongue and the aorta (Fig. 5, left). Other tissues including skin, heart, brain, lung, kidney and liver revealed only a faint signal. In the cases of tendon, skeletal muscle (derived from the hind limb) and spleen, this signal was barely detectable after normal exposure time, but became visible after prolonged exposure of the blot (Fig. 5, right).

Discussion

Fgfr1 is a novel cell surface receptor that is structurally related to the family of the Fgfrs. Owing to this structural relationship, we and others have speculated that it might be involved in the modulation of FGF signaling (1,3).

Here we demonstrate that Fgfr1 is expressed in most tissues of late mouse embryos, but only at very low level. Nevertheless, the expression is high enough to be detectable by Northern blotting. In addition to this basal expression, cartilage and some muscle types express Fgfr1 at fairly high level such that the expression becomes detectable by *in situ* hybridization. Permanent cartilage from the nose, the ribs and the tracheal rings as well as intermediate cartilage from the primordia of bones contain relatively high levels of the Fgfr1 mRNA. In the case of muscle, the expression appears to vary between different muscle types. Some muscle types, including the intercostal muscles, the muscle of the tongue and the muscle of the diaphragm, express relatively high levels of Fgfr1, whereas skeletal muscles from the limbs express it at very low levels. In fact, the musculus biceps femoris showed the lowest level of the Fgfr1 mRNA among all the samples tested in our study. The differences in the relative expression cannot simply be explained by different developmental stages of the particular muscle types because the tongue showed particularly high expression at embryonic day 16 as well as 2 weeks after birth, whereas the muscles of the leg showed very low expression at both stages and even in adult animals (data not shown). It is therefore likely that some functional differences exist between Fgfr1 positive and Fgfr1 negative muscles. The tongue and to some extent also the diaphragm contain multiple interwoven muscle bundles that point in diverse directions (13,14), whereas the muscles from the leg contain bundles that are aligned in parallel relative to each other. It remains to be determined whether the orientation of the bundles are linked in some way with the relative expression of Fgfr1.

Another question relates to the common function of Fgfr1 in two tissues as different as cartilage and muscle. Chondrocytes from cartilage are known to express primarily Fgfr3. On the other hand, myoblasts derived from skeletal muscle express primarily Fgfr1 and Fgfr4. If our hypothesis is correct that Fgfr1 might interact with another Fgfr to modulate FGF signaling (see Introduction) we may speculate that it must be able to combine with more than one Fgfr subtype. It is therefore conceivable that the functions exerted by the novel receptor might differ depending on the particular Fgfr subtype that is expressed in cartilage and muscle.

Recently, Hayashi and coworkers (15) reported on the expression of the homologous receptor from *Xenopus* termed XFGFR1. These authors detected expression in the anterior mesendodermal region at early developmental stages (gastrula, neurula). During the tail bud stage, the XFGFR1 mRNA was found in distinct regions of the forebrain, the eyes, the midbrain-hindbrain boundary, the otic vesicles, the visceral arches and the somites. It is difficult to compare these results with our expression pattern. We did not observe any expression in the brain, the eyes or the spinal cord of late mouse embryos (15-17 days), but we found expression in cartilaginous structures. At an earlier stage (12 days), we could not detect

any signal above background at all. However, mouse embryos of very early stages were not included in our study since this would have required more elaborate techniques such as *in vitro* fertilization. Thus, it remains to be determined whether Fgfr1 will also play a role in the mouse during formation of the neuroectoderm and the central nervous system.

Acknowledgments

This work was supported by the Swiss National Science Foundation (3100A0-102251), the Swiss Foundation for Research on Muscular Diseases, Oncosuisse (OCS-01211-02-2002) and the Novartis Foundation (04A02).

References

1. Wiedemann M and Trueb B: Characterization of a novel protein (FGFR1) from human cartilage related to FGF receptors. *Genomics* 69: 275-279, 2000.
2. Trueb B, Neuhauss SCF, Baertschi S, Rieckmann T, Schild C and Taeschler S: Fish possess multiple copies of fgfr1, the gene for a novel FGF receptor. *Biochim Biophys Acta* 1727: 65-74, 2005.
3. Sleeman M, Fraser J, McDonald M, Yuan S, White D, Grandison P, Kumble K, Watson JD and Murison JG: Identification of a new fibroblast growth factor receptor, FGFR5. *Gene* 271: 171-182, 2001.
4. Kim I, Moon S-O, Yu K-H, Kim U-H, Koh GY: A novel fibroblast growth factor receptor-5 preferentially expressed in the pancreas. *Biochim Biophys Acta* 1518: 152-156, 2001.
5. Szebenyi G and Fallon JF: Fibroblast growth factors as multi-functional signaling factors. *Int Rev Cytol* 185: 45-106, 1999.
6. Ornitz DM and Itoh N: Fibroblast growth factors. *Genome Biol* 2: 3005.1-3005.12, 2001.
7. Trueb B, Zhuang L, Taeschler S and Wiedemann M: Characterization of FGFR1, a novel FGF receptor preferentially expressed in skeletal tissues. *J Biol Chem* 278: 33857-33865, 2003.
8. Wiedemann M and Trueb B: The mouse Fgfr1 gene coding for a novel FGF receptor-like protein. *Biochim Biophys Acta* 1520: 247-250, 2001.
9. Chomczynski P and Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Anal Biochem* 162: 156-159, 1987.
10. Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA and Struhl K: *Current Protocols in Molecular Biology*. Greene Publishing Associates, New York, 1987.
11. Feinberg AP and Vogelstein B: A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. *Anal Biochem* 132: 6-13, 1983.
12. Wälchli C, Koch M, Chiquet M, Odermatt BF and Trueb B: Tissue specific expression of the fibrin-associated collagens XII and XIV. *J Cell Sci* 107: 669-681, 1994.
13. Saito H and Itoh I: Three-dimensional architecture of the intrinsic tongue muscles, particularly the longitudinal muscle, by the chemical-maceration method. *Anat Sci Int* 78: 168-176, 2003.
14. Celli B: The diaphragm and respiratory muscles. *Chest Surg Clin N Am* 8: 207-224, 1998.
15. Hayashi S, Itoh M, Taira S, Agata K and Taira M: Expression patterns of *Xenopus* FGF receptor-like 1/nou-darake in early *Xenopus* development resembles those of planarian nou-darake and *Xenopus* FGF8. *Dev Dynamics* 230: 700-707, 2004.
16. Kaufman MH: *The Atlas of Mouse Development*. 4th edition. Academic Press, San Diego, 2001.